EGZOTech

Gliwice, PolandFounded 201311–50 employeesegzotech.comLinkedIn

EEG and neural monitoring
Neurorehabilitation and assistive tech

EGZOTech is a Poland-based medical technology company developing robotic rehabilitation devices for neurorehabilitation and orthopaedic therapy. Its product portfolio combines electromyography (EMG), robotic-assisted movement and electrostimulation to support physical therapists and help patients regain physical health.

Visit egzotech.com ↗

Founded: 2013
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

EGZOTech’s publicly documented milestones are concentrated in product development, international commercialization and non-dilutive financing rather than frequent corporate announcements. The company received a $1.41 million grant on Apr 1, 2021, following a $717,592 grant on Jun 1, 2020 and a $2.32 million grant on Sep 1, 2016. These awards represent the largest disclosed financing events in its six-round, $4.999 million funding history. Its portfolio now spans Luna EMG, Sidra LEG, Meissa OT and Stella BIO, covering robotic assistance, EMG biofeedback and electrical stimulation across upper-limb, lower-limb and trunk rehabilitation. Website information indicates that more than 350 Luna EMG robots have been delivered worldwide, with commercial activity in more than 20 countries and more than 300 clients in Poland. EGZOTech also describes sales and implementation teams in Germany, the Czech Republic, Italy, Malaysia and the United States. Michal Mikulski remains CEO and Pawel Soja has served as CTO since 2013.

Market position

EGZOTech operates at the intersection of rehabilitation robotics, medical devices and digital health, with a particular focus on neurological and orthopaedic therapy. Its differentiation is hardware-led: Luna EMG combines robotic movement, EMG biofeedback and active-resistive or assistive exercise, while Sidra LEG, Meissa OT and Stella BIO extend the portfolio across lower-limb, upper-limb, hand and portable stimulation use cases. The company’s EGZOConcept approach links EMG-triggered movement with robotic assistance and electrostimulation, giving it a broader modality mix than a single-purpose therapy device. Its stated deployment of more than 350 Luna EMG robots and presence in over 20 countries indicate commercial reach beyond Poland. Relevant competitive categories include established rehabilitation-robotics manufacturers, neurological stimulation providers and hospital physiotherapy-equipment suppliers. EGZOTech’s profile is therefore best characterized as a specialized European medtech manufacturer with an integrated product platform, rather than as a broadly diversified healthcare technology company.

Growth & opportunities

EGZOTech’s trajectory shows a progression from early private financing into grant-supported product and market expansion. It raised $220,000 in a seed round on Mar 28, 2013, followed by an undisclosed seed round involving SATUS and Augere Business Angels Network on Jun 1, 2014 and a €300,000 angel round on Nov 1, 2015, valued at $330,624 in the funding record. The company then secured progressively larger grants: $2.32 million on Sep 1, 2016, $717,592 on Jun 1, 2020 and $1.41 million on Apr 1, 2021. Product breadth expanded from the Luna EMG platform to Sidra LEG, Meissa OT and Stella BIO, creating coverage across whole-body, lower-limb, upper-limb and portable EMG/electrostimulation applications. Website information cites more than 350 Luna EMG deployments worldwide and operations in over 20 countries. The company reports a workforce of more than 70 people in 2024/2025, although the structured employee band remains c_00011_00050.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes EGZOTech distinct

reccy insights

What makes EGZOTech distinct

01Recognized as one of Poland’s largest manufacturers of rehabilitation robots, with more than 350 Luna EMG robots delivered worldwide.
02Combines EMG-triggered movement, robotic assistance and electrostimulation through its EGZOConcept approach.
03Serves healthcare providers in more than 20 countries and has worked with over 300 clients in Poland.
04Maintains sales and implementation teams in Germany, the Czech Republic, Italy, Malaysia and the United States.
05Focuses on automated neurorehabilitation for stroke, spinal cord injuries, neurodegenerative diseases and orthopaedic conditions.

Technology & products4

Technology & products

Luna EMG
A robotic rehabilitation and diagnostic device for upper- and lower-limb and trunk exercises, supporting passive, active-resistive, EMG biofeedback and EMG-driven assistive movements.
Sidra LEG
A lower-limb robotic rehabilitation device featuring dual motors, synchronized electrical stimulation and EMG-triggered movement for neurological and orthopaedic therapy.
Meissa OT
A mobile robotic device for upper-limb and hand rehabilitation using EMG and electrical stimulation to support active and passive therapy movements.
Stella BIO
A portable six-channel electromyography and electrical stimulation device for neurological, orthopaedic, pain and pelvic-floor rehabilitation, with offline operation.

Show all 4 products

+ 1 more: Stella BIO

Similar companies

Show all 6 companies

About EGZOTech

Products: Luna EMG, Sidra LEG, Meissa OT, Stella BIO
Leadership: Michal Mikulski, CEOPawel Soja, CTO
Focus areas: NeuroTechnology, medical devices, digital health, hardware, rehabilitation robotics, neurorehabilitation, physical therapy, EMG
Headquarters: Gliwice, Poland
Founded: 2013
Employees: 11–50
Trademarks: 6